Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 3/20 | 0.40 |
| ▸ | PRKACA | P17612 | 3/20 | 0.40 |
| ▸ | GSK3B | P49841 | 3/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.40 |
| ▸ | CDC7 | O00311 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 3/20 | 0.38 |
| ▸ | CDK7 | P50613 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15181296 | 0.81 | BTK (0.32) | MAP4K4PRKACAGSK3BCLK4ROCK2 | |
| SCHEMBL91460 | 0.77 | PRKACA (0.39) | MAP4K4PRKACAGSK3BCLK4CDC7 | |
| SCHEMBL16680979 | 0.77 | MAP4K4 (0.44) | MAP4K4PRKACAGSK3BCLK4CDC7 | |
| SCHEMBL1317469 | 0.74 | PDPK1 (0.50) | MAP4K4PRKACAGSK3BCLK4CDC7 | |
| SCHEMBL91427 | 0.73 | CLK4 (0.37) | MAP4K4PRKACAGSK3BCLK4CDC7 | |
| SCHEMBL84391 | 0.73 | EIF4A3 (0.39) | MAP4K4PRKACAGSK3BCLK4CDC7 | |
| SCHEMBL1690456 | 0.71 | CDC7 (0.37) | MAP4K4PRKACAGSK3BCLK4CDC7 | |
| SCHEMBL84515 | 0.70 | PDPK1 (0.55) | MAP4K4PRKACAGSK3BCLK4ROCK2 | |
| SCHEMBL22328056 | 0.70 | KDR (0.42) | MAP4K4PRKACAGSK3BCLK4CDC7 | |
| SCHEMBL13084189 | 0.69 | ALOX5AP (0.39) | BTKROCK1PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | MAP4K4 117/4885PRKACA 51/4885GSK3B 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.